Ser253
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser253  -  SRF (human)

Site Information
LTYQVsEsDSSGETK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 13203801

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 2 ) , [32P] bio-synthetic labeling ( 2 ) , mass spectrometry ( 1 ) , mutation of modification site ( 2 ) , peptide sequencing ( 2 ) , phosphoamino acid analysis ( 2 )
Disease tissue studied:
luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) ( 2 ) , breast ( 1 ) , HeLa (cervical) ( 2 )

Downstream Regulation
Effects of modification on biological processes:
transcription, inhibited ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Janknecht R, Ernst WH, Houthaeve T, Nordheim A (1993) C-terminal phosphorylation of the serum-response factor. Eur J Biochem 216, 469-75
8375385   Curated Info